108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
解读虎杖苷 A 在肝纤维化中的作用
Authors Wang S , Wu J, Sun J , Chen W, Tian Z, Huang S , Wang M
Received 25 March 2025
Accepted for publication 1 September 2025
Published 30 September 2025 Volume 2025:19 Pages 8891—8902
DOI https://doi.org/10.2147/DDDT.S530387
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Manfred Ogris
Siqing Wang,1 Jing Wu,2 Jian Sun,1 Wei Chen,3 Zhaochun Tian,4 Shuhong Huang,2 Meng Wang5
1The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China; 2School of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, People’s Republic of China; 3Department of Gastroenterology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 4The Department of Traditional Chinese Medicine Ophthalmology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, People’s Republic of China; 5Department of General Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China
Correspondence: Shuhong Huang, School of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, 6699, Qingdao Road, Jinan, Shandong, 250117, People’s Republic of China, Email shuhonghuang@sdfmu.edu.cn Meng Wang, Department of General Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, 16369, Jingshi Road, Jinan, Shandong, 250014, People’s Republic of China, Email wangmtcm@163.com
Abstract: Liver fibrosis is a dynamic and complex process characterized by the excessive accumulation of extracellular matrix (ECM) components, driven by a heterogeneous population of hepatic myofibroblasts (MFs). Current treatments for liver fibrosis primarily include pharmacological interventions such as antiviral and anti-fibrotic therapies, alongside lifestyle modifications, including dietary changes and alcohol abstinence. However, the therapeutic outcomes remain suboptimal. Existing anti-fibrotic medications are unable to fully reverse liver fibrosis, particularly in its advanced stages, and some drugs may even induce adverse effects. Recently, the challenge of combating liver fibrosis has attracted increasing attention from both the academic community and the general public, leading to extensive research efforts and several significant discoveries. Hepatocyte senescence, an irreversible and inevitable process, plays a crucial role in the onset and progression of various liver diseases. It serves as a key regulatory factor in the development of liver fibrosis, exerting a considerable impact on its progression. Senescent hepatocytes secrete the senescence-associated secretory phenotype (SASP), which interacts with hepatic stellate cells (HSCs), promoting their transformation into MFs. Additionally, SASP fosters a cellular microenvironment conducive to the advancement of hepatic fibrosis, thereby accelerating its progression. This review comprehensively examines the natural flavonoid compound Oroxylin A (OA), which regulates hepatocyte senescence in the context of liver fibrosis. The paper also discusses the current research landscape, trends, and critical challenges related to hepatocyte senescence in liver fibrosis, along with the mechanisms through which OA influences hepatocyte senescence, either promoting or delaying its onset.
Keywords: oroxylin A, liver fibrosis, cell senescence
1The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China; 2School of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, People’s Republic of China; 3Department of Gastroenterology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 4The Department of Traditional Chinese Medicine Ophthalmology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, People’s Republic of China; 5Department of General Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China
Correspondence: Shuhong Huang, School of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, 6699, Qingdao Road, Jinan, Shandong, 250117, People’s Republic of China, Email shuhonghuang@sdfmu.edu.cn Meng Wang, Department of General Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, 16369, Jingshi Road, Jinan, Shandong, 250014, People’s Republic of China, Email wangmtcm@163.com
Abstract: Liver fibrosis is a dynamic and complex process characterized by the excessive accumulation of extracellular matrix (ECM) components, driven by a heterogeneous population of hepatic myofibroblasts (MFs). Current treatments for liver fibrosis primarily include pharmacological interventions such as antiviral and anti-fibrotic therapies, alongside lifestyle modifications, including dietary changes and alcohol abstinence. However, the therapeutic outcomes remain suboptimal. Existing anti-fibrotic medications are unable to fully reverse liver fibrosis, particularly in its advanced stages, and some drugs may even induce adverse effects. Recently, the challenge of combating liver fibrosis has attracted increasing attention from both the academic community and the general public, leading to extensive research efforts and several significant discoveries. Hepatocyte senescence, an irreversible and inevitable process, plays a crucial role in the onset and progression of various liver diseases. It serves as a key regulatory factor in the development of liver fibrosis, exerting a considerable impact on its progression. Senescent hepatocytes secrete the senescence-associated secretory phenotype (SASP), which interacts with hepatic stellate cells (HSCs), promoting their transformation into MFs. Additionally, SASP fosters a cellular microenvironment conducive to the advancement of hepatic fibrosis, thereby accelerating its progression. This review comprehensively examines the natural flavonoid compound Oroxylin A (OA), which regulates hepatocyte senescence in the context of liver fibrosis. The paper also discusses the current research landscape, trends, and critical challenges related to hepatocyte senescence in liver fibrosis, along with the mechanisms through which OA influences hepatocyte senescence, either promoting or delaying its onset.
Keywords: oroxylin A, liver fibrosis, cell senescence